Clinical observation of ticagrelor combined with Compound xueshuantong capsule in the treatment of unstable angina pectoris
- VernacularTitle:替格瑞洛联合复方血栓通胶囊治疗不稳定型心绞痛的临床观察
- Author:
Songbo CHAI
1
;
Yakang DU
1
;
Shujuan ZHANG
2
;
Jiangbo WU
3
;
Weiping ZHANG
1
;
Xiaofei WANG
1
Author Information
1. Dept. of Cardiology，Sanmenxia Hospital of Traditional Chinese Medicine，Henan Sanmenxia 472099，China
2. Dept. of Cardiology，Second Clinical Medical College，Henan University of Chinese Medicine，Zhengzhou 450002，China
3. Dept. of Pharmacy，Sanmenxia Hospital of Traditional Chinese Medicine，Henan Sanmenxia 472099，China
- Publication Type:Journal Article
- Keywords:
unstable angina pectoris;
ticagrelor;
Compound xueshuantong capsule;
frequency of angina attacks
- From:
China Pharmacy
2023;34(23):2901-2905
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the efficacy and safety of ticagrelor combined with Compound xueshuantong capsules in the treatment of unstable angina pectoris. METHODS Totally 120 patients with unstable angina pectoris with deficiency of Qi and Yin combined admitted to Sanmenxia Hospital of Traditional Chinese Medicine from January 2021 to December 2022 were randomly divided into clopidogrel group （group A）， ticagrelor group （group B） and combined medication group （group C）， with 40 patients in each group. In addition to conventional treatment， group A was given clopidogrel orally； group B was given ticagrelor orally； group C was given ticagrelor and Compound xueshuantong capsule orally. After 12 weeks of treatment， the clinical efficacy， frequency of angina attacks， coagulation function indicators， cardiac function indicators， traditional Chinese medicine syndrome efficacy， and the incidence of adverse cardiovascular events and bleeding incidence were evaluated in the 3 groups. RESULTS The total effective rates of group A， group B and group C were 77.5%， 85.0% and 90.0%， respectively. The incidence of adverse cardiovascular events and bleeding events were 7.5%， 7.5% and 5.0% in the respective groups， with no statistically significant difference （P＞0.05）. The frequency of angina attacks， duration of angina attacks and duration of dyspnea were significantly reduced or shortened in all 3 groups after treatment compared to before treatment （P＜0.05）. The frequency of angina attacks in group C was significantly lower than that in groups A and B after treatment （P＜0.05）. The levels of fibrinogen （FBG） and D-dimer in all 3 groups were significantly lower after treatment compared to before treatment （P＜0.05）； group A had significantly higher levels of FBG and D-dimer compared to group B and C （P＜0.05）. The left ventricular end-diastolic diameter and left ventricular end-systolic diameter in all three groups were significantly shorter after treatment， and the left ventricular ejection fraction was significantly higher compared to before treatment （P＜0.05）， but there were no statistically significant differences among those groups （P＞0.05）. The total effective rates of traditional Chinese medicine syndrome efficacy in groups A， B and C were 67.5%， 80.0% and 87.5%， respectively， with group C being significantly higher than group A （P＜0.05）. CONCLUSIONS In addition to conventional treatment， ticagrelor combined with Compound xueguantong capsules can more significantly reduce the frequency of angina attacks in patients with unstable angina pectoris， reduce the levels of FBG and D- dimer， improve traditional Chinese medicine syndrome efficacy， and do not increase the risk of bleeding.
